Jardiance Cost in South Carolina 2026: Prices, Medicaid, Compounded Options

What Is Empagliflozin and Why Do Patients in South Carolina Seek It?

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease. It works by blocking glucose reabsorption in the proximal tubule of the kidney, lowering blood glucose while also producing modest weight loss and blood pressure reduction. South Carolina has one of the highest rates of type 2 diabetes in the southeastern United States, with the CDC estimating that 13.4% of South Carolina adults had diagnosed diabetes as of the most recent Behavioral Risk Factor Surveillance System data, compared with a national average of 11.6% [1]. That disease burden means a large patient population is potentially eligible for empagliflozin therapy.

The FDA first approved empagliflozin (Jardiance) in August 2014 for type 2 diabetes, then expanded the label in 2016 following the EMPA-REG OUTCOME trial results, and again in 2021 and 2022 for heart failure and CKD indications [2]. Each label expansion widened the pool of patients for whom a prescriber can justify the drug, which is why discussions about its cost and access have grown more pressing. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% relative risk reduction in cardiovascular death versus placebo over a median follow-up of 3.1 years in patients with type 2 diabetes and established cardiovascular disease [3]. That single outcome redefined the drug's clinical profile and made cost barriers feel more consequential.

South Carolina residents seeking Jardiance face a combination of high list price, inconsistent insurance coverage, and a Medicaid program that has not placed the drug on its preferred drug list for most patient categories. The sections below break down every cost pathway available to a South Carolina patient in 2026.

How Much Does Jardiance Cost in South Carolina?

The cash price for Jardiance in South Carolina is approximately $680 per month for a 30-day supply of either the 10 mg or 25 mg tablet in 2026. That figure reflects the manufacturer's wholesale acquisition cost and holds across major retail chains including CVS, Walgreens, Publix, and Walmart in the state. Without insurance or a discount program, a South Carolina patient pays between $8,000 and $8,200 annually for this single medication [4].

GoodRx and similar discount platforms may reduce the cash price modestly at certain South Carolina pharmacies, sometimes to the $580 to $620 range, though these discounts require using GoodRx's negotiated pricing and forgoing insurance billing for that fill. A patient should ask the pharmacist to price-check both routes before each fill, since the discount varies by pharmacy and month.

The 90-day supply price at retail pharmacies in South Carolina typically runs about $1,900 to $2,040, which is slightly less expensive on a per-day basis than the 30-day fill. Mail-order pharmacy options through most commercial insurance pharmacy benefit managers offer a similar 90-day rate when Jardiance appears on the plan formulary.

For patients who do qualify for commercial insurance coverage, the actual out-of-pocket cost depends heavily on tier placement. Most commercial formularies in South Carolina place Jardiance on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), generating copays between $45 and $120 per month after deductible, though some high-deductible plans require the full list price until the deductible is met [5].

Does South Carolina Medicaid Cover Jardiance?

South Carolina Medicaid (Healthy Connections) does not cover Jardiance for most beneficiaries as of 2026. The South Carolina Department of Health and Human Services (SCDHHS) Healthy Connections preferred drug list places SGLT2 inhibitors in a restricted coverage category. Coverage may be obtained through prior authorization (PA) for specific patient populations, but the PA criteria are narrow and frequently require documented failure of at least two other diabetes medications, a confirmed diagnosis of heart failure, or CKD with albuminuria above a specified threshold [6].

The American Diabetes Association's 2024 Standards of Care in Diabetes state that "SGLT2 inhibitors are recommended for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD to reduce cardiorenal risk" [7]. Despite this strong guideline language, South Carolina Medicaid's reimbursement structure has not yet aligned with those recommendations across all eligible patient categories.

Patients on South Carolina Medicaid who have a concurrent diagnosis of heart failure with reduced ejection fraction (HFrEF) have the strongest PA pathway, as federal Medicaid guidance issued following the EMPEROR-Reduced trial data (N=3,730) supports coverage for heart failure. EMPEROR-Reduced showed a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for heart failure with empagliflozin versus placebo [8]. Patients should ask their prescriber to document this diagnosis explicitly in the PA request and to attach supporting echocardiographic or clinical data.

South Carolina Medicaid beneficiaries who do not qualify through PA should ask their provider about alternative SGLT2 inhibitors (dapagliflozin, canagliflozin) that may carry different PA criteria, or about the 503A compounded empagliflozin pathway described below.

Is Compounded Empagliflozin Legal in South Carolina?

Compounded empagliflozin prepared by a state-licensed 503A compounding pharmacy is legal in South Carolina. A 503A pharmacy compounds medications for individual patient prescriptions, operating under state board of pharmacy oversight and USP standards rather than FDA manufacturing standards [9]. South Carolina's Board of Pharmacy licenses and inspects compounding pharmacies operating within the state and accepts valid prescriptions for compounded empagliflozin.

The cost difference between compounded empagliflozin and brand Jardiance is substantial. Some 503A compounding pharmacies serving South Carolina patients price compounded oral empagliflozin capsules at $40 to $80 per month, a fraction of the $680 brand price. A small number of telehealth platforms have integrated compounded empagliflozin into their formularies at costs below $50 per month, though the exact price varies by pharmacy and formulation.

Patients and prescribers should understand key caveats. Compounded medications are not FDA-approved products. The FDA has not evaluated compounded empagliflozin for safety, potency, or bioequivalence to Jardiance. The FDA's guidance on SGLT2 inhibitor compounding notes that compounded versions lack the clinical trial data that supports brand labeling [10]. A prescriber must document a clinical rationale for the compounded formulation, typically citing a patient's inability to afford the brand medication or a need for a customized dose not commercially available.

South Carolina prescribers considering compounded empagliflozin for their patients should verify that the compounding pharmacy holds a current South Carolina Board of Pharmacy license, uses a Certificate of Analysis from a third-party laboratory for each batch, and follows USP Chapter 795 standards for non-sterile compounding. Patients receiving compounded empagliflozin should have the same laboratory monitoring (renal function, urinalysis, HbA1c) as patients on the brand product.

Which Insurance Plans Cover Jardiance in South Carolina?

Coverage for Jardiance in South Carolina varies widely across insurance plan types. Understanding which tier a plan places the drug on, and what the associated prior authorization requirements are, determines real out-of-pocket cost more than any other single factor.

Medicare Part D. Medicare Part D plans in South Carolina are required to cover at least two SGLT2 inhibitors per formulary category, but specific coverage of Jardiance versus a competitor depends on each plan's negotiated rebate. In 2026, the Inflation Reduction Act's $2,000 out-of-pocket cap on Part D applies, meaning no Medicare beneficiary should pay more than $2,000 annually for covered drugs, including Jardiance when it appears on the plan's formulary [11]. Patients can use Medicare's Plan Finder tool to identify South Carolina Part D plans that list Jardiance as a covered drug.

ACA Marketplace Plans. Plans sold through healthcare.gov in South Carolina are required to cover prescription drugs, but the tier placement of Jardiance is plan-specific. A bronze plan with a high deductible may require the full cash price during the deductible period. A silver or gold plan may offer a $60 to $100 copay per month once the deductible is met.

Employer-Sponsored Insurance. Most large-group employer plans operating in South Carolina cover Jardiance at Tier 3 or Tier 4 of their formulary. The Boehringer Ingelheim and Lilly savings card (detailed below) stacks with most commercial employer plans and may reduce the patient's net copay to $10 per month [12].

TRICARE and VA. Veterans Affairs patients in South Carolina receive empagliflozin through the VA national formulary when clinically appropriate. TRICARE covers Jardiance under its pharmacy benefit with a copay structure that depends on formulary tier and pharmacy type (military pharmacy, TRICARE retail, TRICARE mail order).

How the Boehringer Ingelheim and Lilly Jardiance Savings Card Works in South Carolina

The Jardiance savings card, offered jointly by Boehringer Ingelheim and Eli Lilly, allows eligible commercially insured patients in South Carolina to pay as little as $10 per month for a 30-day or 90-day supply. The card is activated at JardianceHCP.com or through the prescriber's office and applies at participating pharmacies including CVS, Walgreens, Rite Aid, Kroger, and most independent pharmacies in South Carolina [12].

Eligibility requirements for the savings card include: the patient must have commercial insurance (not government-funded insurance such as Medicare, Medicaid, TRICARE, or VA), must be a US resident, and must use the card at a participating retail pharmacy. The card covers up to a specified maximum savings per fill, with program terms updated annually. Patients should re-enroll or verify card status at the start of each calendar year, as 2026 program terms may differ from 2025.

For South Carolina patients without any insurance, the savings card does not apply. Uninsured patients should instead contact the Boehringer Ingelheim Patient Assistance Program (PAP), which provides Jardiance at no cost to qualifying patients whose household income falls below 400% of the federal poverty level [13]. The application process requires a prescriber attestation and proof of income.

Can a South Carolina Patient Get Jardiance via Telehealth?

Telehealth prescribing of Jardiance is permitted in South Carolina. South Carolina law allows licensed physicians, nurse practitioners, and physician assistants to prescribe medications following a synchronous telehealth visit that meets the standard of care for an in-person evaluation. The prescriber must conduct a clinically appropriate evaluation, review the patient's medication list and renal function, and establish a valid patient-prescriber relationship before issuing the prescription [14].

South Carolina's Telehealth Alliance and the state's DHEC licensing framework explicitly permit telehealth prescribing of non-controlled oral medications including SGLT2 inhibitors. A prescriber must hold a valid South Carolina license and the patient must be physically located in South Carolina at the time of the telehealth encounter.

Several national telehealth platforms now prescribe empagliflozin to South Carolina residents, pairing the prescription with compounded empagliflozin through a 503A pharmacy or with brand Jardiance through retail channels. Patients should confirm the prescriber's South Carolina license number and the pharmacy's South Carolina registration before completing any telehealth platform order.

Telehealth prescribing does not waive the requirement for baseline and periodic laboratory monitoring. The FDA label for Jardiance requires assessment of renal function before initiating therapy and recommends against use in patients with an eGFR below 20 mL/min/1.73 m2 for CKD indications or below 30 mL/min/1.73 m2 for the diabetes indication [2]. A telehealth prescriber must obtain these laboratory values, typically through lab orders fulfilled at a patient-convenient location such as LabCorp or Quest in South Carolina.

Clinical Evidence Supporting Empagliflozin Use

South Carolina patients and their prescribers should understand the evidence base that gives empagliflozin its clinical standing. Three major trials define the drug's benefit profile.

EMPA-REG OUTCOME (N=7,020) was a randomized, placebo-controlled trial published in the New England Journal of Medicine in 2015. Patients had type 2 diabetes and established cardiovascular disease. Empagliflozin 10 mg or 25 mg daily reduced the primary composite outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [3]. Cardiovascular death alone fell by 38% (hazard ratio 0.62 to 95% CI 0.49 to 0.77).

EMPEROR-Reduced (N=3,730) enrolled patients with heart failure and ejection fraction of 40% or below. Empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) over a median follow-up of 16 months [8].

EMPEROR-Preserved (N=5,988) extended those findings to patients with heart failure and preserved ejection fraction (HFpEF, ejection fraction above 40%). Empagliflozin 10 mg reduced the primary composite outcome by 21% (hazard ratio 0.79 to 95% CI 0.69 to 0.90, P<0.001), making it one of the first therapies to show benefit in HFpEF [15].

The EMPA-KIDNEY trial (N=6,609) examined patients with CKD (eGFR 20 to 45 mL/min/1.73 m2 or eGFR 45 to 90 mL/min/1.73 m2 with urinary albumin-to-creatinine ratio of at least 200 mg/g). Empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% relative to placebo (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001) [16].

These four trials together form the clinical rationale that guidelines from the American Diabetes Association [7], the American College of Cardiology, and Kidney Disease Improving Global Outcomes (KDIGO) use to position empagliflozin as a preferred agent across multiple indications. That guideline strength is also why access barriers in a high-burden state like South Carolina carry real population health consequences.

Monitoring Requirements for South Carolina Patients on Empagliflozin

All patients prescribed empagliflozin, whether through brand Jardiance or a compounded formulation via a South Carolina 503A pharmacy, require the same baseline and follow-up laboratory work. The FDA-approved prescribing information specifies assessment of renal function prior to initiation and periodically thereafter [2]. Standard clinical practice includes:

Baseline: serum creatinine, eGFR, urinary albumin-to-creatinine ratio (uACR), HbA1c, complete metabolic panel, and urinalysis. South Carolina patients can complete these at any LabCorp or Quest Diagnostics location, both of which have multiple sites statewide.

Follow-up at 3 months: repeat eGFR and HbA1c to assess glycemic response and confirm renal tolerability. The ADA's 2024 Standards of Care in Diabetes state that "SGLT2 inhibitors should not be initiated when eGFR is below 20 mL/min/1.73 m2" and that the glycemic benefit diminishes substantially when eGFR falls below 45 mL/min/1.73 m2 [7].

Patients should receive education about the signs of diabetic ketoacidosis (DKA), a rare but serious adverse effect of SGLT2 inhibitors that can occur even with near-normal blood glucose levels. The FDA issued a safety communication on euglycemic DKA in 2015, and clinicians should advise patients to hold empagliflozin 3 to 4 days before elective surgery or periods of prolonged fasting [17].

Genital mycotic infections occur in approximately 10.4% of women and 4.2% of men treated with empagliflozin in clinical trial data, compared with 1.8% and 0.6% respectively with placebo, per pooled Phase III trial analyses [18]. South Carolina prescribers should discuss this risk proactively and advise patients on hygiene measures.

What Is the Cheapest Way to Get Jardiance in South Carolina?

The lowest-cost legally available option for most South Carolina residents depends on insurance status.

Commercially insured patients: use the Boehringer Ingelheim and Lilly savings card at a participating retail pharmacy in South Carolina. The $10 monthly copay is the floor for this group [12].

Medicare Part D enrollees: select a South Carolina Part D plan that places Jardiance on its formulary, then benefit from the 2026 $2,000 annual out-of-pocket cap under the Inflation Reduction Act [11].

Medicaid beneficiaries without PA approval: request a prior authorization through a prescriber who documents heart failure or CKD indications, or inquire about alternative SGLT2 inhibitors on the preferred drug list, or explore the compounded empagliflozin pathway through a South Carolina 503A pharmacy.

Uninsured patients: apply to the Boehringer Ingelheim Patient Assistance Program for free brand medication if income qualifies, or obtain a prescription for compounded empagliflozin through a telehealth provider and fill it at a licensed South Carolina 503A compounding pharmacy at $40 to $80 per month [13].

Patients should re-evaluate their access strategy annually, as formulary tier placements, savings card program terms, and Medicaid preferred drug lists all update on January 1 of each year.